UK-CAB 62: Generic HIV drugs

Friday 21 April 2017

DRAFT Programme

09.30-09.40 Arrival, tea and refreshments
09.40-10.00 Welcome and introductions, UK-CAB updates, Company pre-meeting (Garry to lead)
10.00-11.30 Company meeting: MSD
11.30-11.45 BREAK
11.45-12.30 Feedback on MSD, Conferences feedback

Conferences feedback: CROI, BHIVA

12.30-14.00 LUNCH
14.00-15.15 Invited speakers:

  1. Switching to generic ARVs (commissioning) – Janette Harper, NHS England
  2. Switching to generic ARVs (HIV pharmacist) – Nadia Naous, Imperial College NHS Trust
15.15-16.00 More CROI feedback; community reps feedback
16.00-16.10 BREAK
16.10-16.55 Reflection and feedback of the meeting; member updates
16.55 AOB
17.00 Meeting close

Background reading to follow

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Published: April 15, 2015
Last edited: March 3, 2017